Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study by Dewaraja, Yuni K. et al.
Use of Integrated SPECT/CT Imaging for Tumor Dosimetry
in I-131 Radioimmunotherapy: A Pilot Patient Study
Yuni K. Dewaraja,1 Scott J. Wilderman,1 Kenneth F. Koral,1 Mark S. Kaminski,2 and Anca M. Avram1
Abstract
Integrated systems combining functional (single-photon emission computed tomography; SPECT) imaging with
anatomic (computed tomography; CT) imaging have the potential to greatly improve the accuracy of dose
estimation in radionuclide therapy. In this article, we present the methodology for highly patient-specific tumor
dosimetry by utilizing such a system and apply it to a pilot study of 4 follicular lymphoma patients treated with
I-131 tositumomab. SPECT quantification included three-dimensional ordered-subset expectation-maximization
reconstruction and CT-defined tumor outlines at each time point. SPECT=CT images from multiple time points
were coupled to a Monte Carlo algorithm to calculate a mean tumor dose that incorporated measured changes in
tumor volume. The tumor shrinkage, defined as the difference between volumes drawn on the first and last CT
scan (a typical time period of 15 days) was in the range 5%–49%. The therapy-delivered mean tumor-absorbed
dose was in the range 146–334 cGy. For comparison, the therapy dose was also calculated by assuming a static
volume from the initial CT and was found to underestimate this dose by up to 47%. The agreement between
tracer-predicted and therapy-delivered tumor-absorbed dose was in the range 7%–21%. In summary, malignant
lymphomas can have dramatic tumor regression within days of treatment, and advanced imaging methods
allow for a highly patient-specific tumor-dosimetry calculation that accounts for this regression.
Key words: patient-specific dosimetry, radioimmunotherapy, SPECT quantification, SPECT=CT imaging, tumor
regression
Introduction
Some of the best response rates with radionuclide therapyhave been achieved in non-Hodgkin’s lymphoma (NHL),
which is considered to be a relatively radiosensitive malig-
nancy that may be effectively treated with low-dose-rate
radiation.1 Tositumomab is a monoclonal antibody that selec-
tively binds to CD20 on the surface of normal and malignant
B-cells and can be labeled with I-131 to yield I-131-labeled
tositumomab (the Bexxar therapeutic regimen, GlaxoSmith-
Kline, Research Triangle Park, NC). At our university, I-131
tositumomab radioimmunotherapy (RIT) was evaluated as
initial treatment for advanced follicular lymphoma and re-
sulted in a 95% response and a 75% complete response.2 In
patients previously treated with chemotherapy, the reported
overall response ranged from 47% to 68%, and the complete
response ranged from 20% to 38%. While these results are
promising, there is much room for improving efficacy with
individualized treatment planning.
For effective individualized treatment planning, it is im-
perative that methods are developed for accurate dosimetry
and that correlations are established between tumor-dose
response and normal organ-dose toxicity, as well as between
absorbed doses predicted by the tracer study and those de-
livered by the therapy. Limited previous I-131 RIT patient
studies investigating the tracer-predicted and the therapy-
delivered tumor doses report good agreement,3 as well as
considerable variation.4 It is anticipated that concord be-
tween tracer and therapy studies will improve with the
availability of more accurate imaging=quantification techni-
ques. It is, however, possible that changes in biodistribution
occur for reasons such as altered clearance of therapy admin-
istration due to the radiobiologic damage delivered to ma-
lignant tumor cells.4 In the majority of clinical radionuclide
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therapy studies, statistically significant tumor-dose-response
correlations have not been established,1,5–7 possibly due to
inaccuracies in dose estimation. In these past studies in-
vestigating tracer-therapy and dose-response correlations,
pharmacokinetics from planar imaging or methods combin-
ing single-photon emission computed tomography (SPECT)
with planar imaging were used to determine cumulated
tumor activities. Quantitative planar-imaging methods are
suboptimal due to interference from activity in overlying and
underlying tissue and, unlike SPECT, require careful back-
ground subtraction. In past RIT patient studies, the model-
based Medical Internal Radiation Dose (MIRD) Committee
‘‘S-factor’’ approach has been used for the dosimetry calcu-
lation, except in one study where patient-specific three-
dimensional (3D) calculations were carried out.7 A review
article discusses the significant improvement that can be
achieved with image-based patient-specific dosimetry, which
couples patient anatomy and activity distribution with
Monte Carlo radiation transport.8
The recent availability of integrated SPECT=CT, where
patient anatomy and radionuclide distribution can be im-
aged sequentially in a single session, is a turning point for
SPECT-activity quantification and patient-specific dosimetry.
The computed tomography (CT) spatial resolution of such
systems is typically on the order of 1 mm, while the SPECT
resolution is around 5–10 mm. The higher resolution co-
registered CT can be used to improve the SPECT recon-
struction, to delineate tumor and organ volumes of interest,
and to define the patient anatomy for Monte Carlo–based
dose estimation. When CT anatomic information is available
from integrated imaging at multiple time points, changes in
tumor volume can be measured and included in the dosim-
etry calculation. This is especially important with malignant
lymphomas, which can be highly sensitive to radiation and
can have dramatic tumor regression within days of treat-
ment.9 However, in most studies thus far, a fixed tumor mass
typically determined from a single baseline CT has been used
for the dosimetry calculation. The assumption of a constant
mass for a tumor that is actually regressing results in an
underestimation of the absorbed dose because of the inverse
relationship between dose and mass for a given uptake. Two
previous studies discuss the significance of tumor regression
in dosimetry for I-131 RIT and include a time-varying tumor
mass in their MIRD-based dosimetry approach.10,11
In two recent studies, integrated SPECT=CT-imaging-
based tumor-organ dosimetry was demonstrated in a patient
with thyroid cancer,12 and bone marrow dosimetry was
demonstrated in NHL patients undergoing RIT.13 In the
present study, we present methodology for highly patient-
specific tumor dosimetry, which accounts for changes in
tumor volume measured with an integrated system. The do-
simetry was carried out by coupling functional (SPECT) and
anatomic (CT) images from multiple time points with a Monte
Carlo algorithm previously developed at our institution.14
The methodology was applied to a pilot study of 4 follicular
lymphoma patients treated with I-131 tositumomab and
pharmacokinetics, and tumor dosimetry results from tracer
and therapy imaging are presented. The focus of the present
work was on using advanced imaging methods to carry out
an accurate patient-specific calculation of mean tumor dose,
rather than on 3D dose-distribution calculations. For 3D dose-
distribution computations to be meaningful, tumor voxels
from multiple time points need to be accurately registered,
and in the case of deforming=regressing tumors (such as those
seen in the present patient study), this problem is nontrivial
and is the focus of a different study.15 Normal organ dosim-
etry was not carried out because, in this pilot study, the focus
was on tumor dosimetry, and the imaging field of view (FOV)
in the axial direction was selected such that the tumor was in
the center, and as a result, normal organs of interest in RIT
(such as the kidney, liver, and spleen) were not included or
only partially included in the FOV.
Materials and Methods
Patients
Four (4) refractory follicular NHL patients undergoing
I-131 radioimmunotherapy at our clinic volunteered for this
research study involving multiple scans on the integrated
SPECT=CT system. (The clinical protocol only involves
planar imaging.) The clinical protocol for drug administra-
tion consisted of two steps.16 In step 1 (tracer administra-
tion), on day 0, patients received an infusion of unlabeled
(cold) tositumomab, followed by an infusion of tositumomab
labeled with 185 MBq (5 mCi) of I-131. In step 2 (therapy
administration), which was 8 days after step 1, patients re-
ceived an infusion of the same amount of unlabeled tositu-
momab, followed by an infusion of tositumomab labeled
with an amount of I-131 (Table 1) calculated to deliver a
nominal whole-body absorbed dose of 75 cGy, based on
clinical post-tracer planar imaging computations.
SPECT=CT acquisition and reconstruction
Patients were imaged on a Siemens Symbia TruePoint
SPECT=CT scanner (Hoffman Esta, IL) with a six-slice CT
capability. Each patient was imaged at three time points
within 6 days after the tracer administration and at three time
Table 1. Administered Activity and Summary of Tracer and Therapy Pharmacokinetics
for the Whole Body Within the SPECT FOV
Patient 1 Patient 2 Patient 3 Patient 4
Administered therapy activity 2.82 GBq 3.50 GBq 3.92 GBq 3.77 GBq
Effective half-life (tracer) 68 hours 67 hours 75 hours 69 hours
Effective half-life (therapy) 59 hours 68 hours 61 hours 64 hours
Residence time (tracer) 30 hours 21 hours 22 hours 28 hours
Residence time (therapy) 28 hours 18 hours 22 hours 26 hours
SPECT, single-photon emission computed tomography; FOV, field of view.
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points within the first 10 days following therapy administra-
tion. The first tracer-imaging time point was within 1–2 hours
after the administration, but due to dead time and radiation
exposure considerations, the earliest therapy imaging time
point was limited to 1–2 days after the administration. The
SPECT data were acquired by using a high-energy parallel-
hole collimator and the following specifications: 180 degrees
and 30 stops per head; 40 seconds per stop; body contouring;
20% photopeak at 364 keV; two adjacent 6% scatter-correction
windows; and a 128128 matrix with a pixel size of 4.8 mm.
The CT component of acquisition used full-circle rotation,
130 kV, 35 mAs, and 5-mm slices. The CT scan time was less
than 20 seconds and was obtained without contrast and
without a breath hold. The X-ray exposure each patient re-
ceived due to each low-dose CT scan was 0.28 rem.17 The CT
data were reconstructed with a 512512196 matrix and
0.980.982 mm voxel size, using commercial ESOFT (Sie-
mens) software.
SPECT reconstruction was carried out by using a 3D
ordered-subset expectation-maximization (3D OSEM) algo-
rithm developed at our institution,18 instead of the com-
mercial software of the integrated system. This allowed for
dead-time correction of the post-therapy projection data,
based on a paralyzable model and the measured dead-time
constant of the SPECT system.19,20 Data were reconstructed
by using 15 iterations and 6 subsets and included 3D depth-
dependent detector-response compensation, attenuation
correction, and scatter correction. The detector response was
determined from point-source measurements in air and was
modeled by a rotationally symmetric single exponential
added to a Gaussian.18 Effect of the noncircular orbit was
accounted for in the depth-dependent detector-response
functions by retrieving the radial position information from
the header of the SPECT-projection data. For nonuniform
attenuation correction, the CT-based attenuation map from
the commercial software was used. For scatter correction,
a triple-energy-window scatter estimate was included in
the OSEM algorithm in a manner appropriate for Poisson
statistics.21 The reconstructed SPECT counts were
converted to activity by using a calibration factor deter-
mined from a measurement with a known amount of I-131
activity in a 100-mL plastic sphere centered in a water-filled
elliptical phantom. Recovery coefficients for partial volume
compensation in small volumes22 were not utilized in
this study because the tumors analyzed were large
(39–408 mL).
Tumor definition and time-activity data
Independent of SPECT, tumors were outlined on CT at each
time point, slice by slice, by a nuclear medicine specialist with
radiology CT training, utilizing visualization tools to enhance
contrast and magnification. All tumors of significant size that
were within the camera FOV were outlined (2 tumors in pa-
tient 1, 2 in patient 2, 1 in patient 3, and 1 in patient 4). The
tumor volume of interest at each time point was applied to the
corresponding coregistered quantitative SPECT image to
generate the tumor time-activity data. For tumor, where the
uptake is noninstantaneous, a biexponential fit was carried
out, including the (0.0) point. When fitting the post-therapy
data, the first post-tracer time point (measured within 1–2
hours after administration) was included in the fit because of
the lack of an early post-therapy imaging time point. Al-
though, in past studies, tumor time-activity data has been
typically fitted with monoexponentials, we used a biexpo-
nential to better model both the noninstantaneous uptake and
clearance phases. The residence time estimates derived from
using mono- and biexponential fitting have been compared in
previous studies.3,23
SPECT-based time-activity data were also generated for
the ‘‘whole body.’’ Because of the limited FOV of the SPECT
camera in the axial direction (39 cm), the whole body is de-
fined in this study as the total body section that is within the
SPECT camera FOV. For the whole body, there is instanta-
neous uptake, and so, a monoexponential was used to fit the
time–activity data.
Tumor dosimetry
The DPM (dose planning method) Monte Carlo electron
and photon transport program24 designed for radiation
absorbed-dose computations in external beam radiotherapy
was adapted and validated for our present application in
internal emitter therapy.14 In the present study, for each time
point, the inputs to DPM were the coregistered SPECT
image, CT-derived density map, and the CT-defined tumor
outlines. To obtain the density map, the previously described
CT-based attenuation map was converted to a map of den-
sities (r(x,y,z)) by dividing each attenuation coefficient voxel
value (m364(x,y,z)) by the mass attenuation coefficient (m=r) at
364 keV. This method is based on the observation that at the
energy of interest, m=r shows little variation between tis-
sue.25 The output from DPM at a given time point was the
3D absorbed-dose-rate map and summary tables computed
for that time point. For the 512512196 matrix, the time to
generate low-uncertainty DPM dose-rate distributions sim-
ulating 1 billion decays was 2.8 hours on a 3-GHz Power Mac
system (Apples). The photon cut-off was set at 4 keV and the
electron cut-off was set at 200 keV, since the range in water of
an electron of this energy (approximately 0.5 mm) is much
less than the voxel dimensions.
At each time point, the DPM output summary tables for
each predefined tumor provide the absorbed-dose-rate
averaged over the volume, dDTUMdt , in units of mGy=MBq.s, as
well as the fraction of that dose rate that is due to self-irra-
diation, fTUM, and the fraction due to irradiation from the
rest of the body, fRB. These quantities from DPM can then be
combined with the SPECT-derived values for the relative
source strength for the tumor (rTUM) and rest of the body
(rRB) at the given time point and the time-integrated cumu-
lated activity in the tumor (ÃTUM) and the rest of the body
(ÃRB) to determine the mean absorbed dose to the tumor,




fTUM  ~ATUM=rTUMþ fRB  ~ARB=rRB
 
(1)
The scaling by the relative source strength factors is neces-
sary to account for differences between the relative cumu-
lated activities in the tumor and rest-of-the-body and the
relative activities in tumor and rest of the body at the specific
time point for which the DPM results were derived.
To incorporate the changing tumor mass, the calculation
of mean absorbed dose, using Equation 1, was carried out
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over three time periods. (The three time periods were: zero to
T1, T1 to T2, and T2 to infinity. Here, T1 is the midpoint of the
first and second imaging time point and T2 is the midpoint of
the second and third time points.) The time-activity curves
were divided into the three time periods, and the cumulated
activity for each period was determined. For each period, the
DPM absorbed-dose rate and other parameters of Equation 1
were also determined by using SPECT=CT images and tumor
outlines corresponding to each of the three imaging time
points. The doses computed by using Equation 1 for each of
the three time intervals were then summed to obtain the total
mean absorbed dose to the tumor. The therapy-delivered
absorbed dose to the tumor was calculated based on data
from the three post-therapy imaging points, while the tracer-
predicted absorbed dose to the tumor was calculated by
scaling the results based on data from the three post-tracer
imaging points by the ratio of therapy to tracer administered
activity.
In SPECT-based patient-specific dosimetry, the contribu-
tion to mean tumor dose from activity outside the camera
FOV is ignored because the activity map on which the cal-
culation is based is only available for the FOV. Because the
rest-of-the-body contribution to tumor dose falls off rapidly
with distance from the tumor, ignoring activity outside the
FOV is not a significant source of error when the tumor is




Figure 1 shows typical slices with tumor outlines dis-
played on fused post-therapy SPECT=CT images. Figure 1A
depicts uptake in massive left pelvic lymphadenopathy
surrounding the external and internal iliac vascular bundle
in patient 1. Figure 1B depicts increased activity in tumor
along the right common iliac lymph nodal chain in patient 2.
Fainter activity is seen contralaterally, reflecting intravascu-
lar blood pool activity of 131-I tositumomab. Figure 1C
shows intensely focal activity in the right inguinal lymph-
adenopathy in patient 2 and fainter activity in the testicles.
Figure 1D shows uptake in a large pelvic tumor surrounding
and encasing multiple small-bowel loops in patient 3. Sig-
nificant activity is also seen in the femoral artery and vein.
Figure 1E shows activity distribution in a massive retroper-
itoneal lymphadenopathy in the para-aortic and aortocaval
space in patient 4. The image also shows significant uptake
in the liver and normal organs in close proximity to the
tumor, such as kidneys, aorta, and bowel.
While there is intense focal activity uptake within the CT-
defined tumor boundary in Figure 1A, 1B, and 1C, there is
less concord between the anatomic tumor outline and SPECT
uptake in Figure 1D and 1E. This is because of the nonuni-
form activity distribution within the tumor outline and be-
cause these tumors encase and compress or are adjacent to
normal anatomic structures that have substantial back-
ground activity. In Figure 1D, the nonuniformity likely re-
flects 131-I tositumomab pooling in the mesenterial
vasculature associated with the bowel loops, which are en-
cased by the tumor. In Figure 1E, the tumor outlined as a
single volume is a conglomeration of multiple enlarged
lymph nodes, hence the uptake is nonuniform within the
outline. In addition, the uptake can be nonuniform due to
differences in the tumor biology.
Tumor shrinkage
The initial tumor volume defined on the first scan is given
in Table 2. The measured tumor shrinkage during tracer
imaging and during therapy imaging, and the total tumor
shrinkage, defined as the percent difference between the
volumes drawn on the first post-tracer SPECT=CT scan and
on the last post-therapy SPECT=CT scan (a typical time pe-
riod of 15 days), is also given in Table 2. Shrinkage was most
significant (up to 49%) for the tumors of patients 1 and 2 and
these reductions in tumor volumes were clearly evident on
CT (Figure 2). In patient 1, the reduction in tumor volume
was significant only after the therapy administration, while
in patient 2, significant volume reduction (up to 23%) was
measured after just the tracer administration.
Independent of the regression measured by the present
SPECT=CT research study the clinical response classification
for these patients was also available from the clinical proto-
col. As part of their standard clinical care, based on post-
therapy clinical CT, patient response was categorized as
complete response (CR), partial response (PR) or progressive
disease (PD) as defined in reference 2. The clinical response
for the patients were: patient 1, CR at 6 months; patient 2, CR
at 6 months; patient 3, PD at 6 weeks; patient 4, PD at 10
weeks.
Time-activity data
Whole body. At the first post-therapy time point, the
main window count rate was up to 18,000 counts per second
and dead-time correction increased the counts by up to 8%,
but by less than 2% at subsequent post-therapy time points.
The tracer and therapy whole-body time-activity curves with
monoexponential fitting are compared in Figure 3 for a
typical patient. Here, %ID is the measured activity normal-
ized by the injected activity; hence, if tracer and therapy
pharmacokinetics are similar, we expect concord between
the two curves. The effective half-lives and residence times
(obtained by integrating the fitted curves) are compared in
Table 1. On average, the agreement between tracer and
therapy data for the whole body is within 10% for the ef-
fective half-life and within 8% for the residence time.
Based on the fit to the time-activity data, the remaining
activity from the tracer injection at the time of the therapy
administration (8 days later) was calculated. In all cases, the
remaining tracer activity was <1 mCi, which was less than
1% of the therapy administration; hence, it is not expected to
affect the therapy data.
Tumor. Figure 4 shows representative biexponential fit-
ted curves of tumor time activity for each patient. Note that
the last post-therapy data point for patient 2 was not avail-
able due to camera malfunction. For tumor, unlike for the
whole body, the concord between tracer and therapy time-
activity data varied significantly from patient to patient and
from time point to time point, as evident in Figure 3. The
tumor residence times determined from tracer and therapy
imaging are compared in Table 2 and agree to within 22%,
on average.
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Tumor dosimetry
The therapy delivered mean tumor-absorbed dose is given
in Table 2 and ranged from 146 to 334 cGy. As discussed
previously, this dose was determined over three time peri-
ods, hence accounting for any changes in the tumor volume
measured over the multiple post-therapy time points. For
comparison, the therapy-delivered dose was also calculated
by assuming a static tumor volume from the initial post-
tracer CT for the DPM dose-rate calculation (last row of
Table 2). In both cases, the same therapy residence time was
used for the dose calculation, and only the tumor volumes
and dose rates differed. For the tumors of patients 1 and 2,
where regression was most significant, the assumption of a
static tumor volume leads to a 20–47% underestimation of
the therapy-delivered dose because of the inverse relation-
ship between absorbed dose and mass at a given activity
uptake.
In Table 2, the therapy-delivered mean tumor-absorbed
dose determined using the three post-therapy time points is
compared with the tracer-predicted mean tumor-absorbed
dose determined from using the three post-tracer time
FIG. 1. Fused single-photon emission computed tomography (SPECT) and computed tomography (CT) images from the
integrated system showing (A) pelvic tumors of patient 1, (B) iliac tumor of patient 2, (C) inguinal tumor of patient 2, (D)
pelvic tumor of patient 3, and (E) abdominal tumor of patient 4. Tumor outlines were defined on CT independent of SPECT.
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points. The agreement between the predicted and delivered
doses ranged from 7% to 21% and was within 15%, on av-
erage. The estimated Pearson’s correlation between the pre-
dicted and delivered doses was 0.90 and the p-value for
testing whether the correlation was different from zero was
0.013. The tumor regression affects both the uptake and the
dose, and for this limited sample size, reasonable agreement
was achieved between the tracer-predicted and the therapy-
delivered doses when the change in tumor volume was in-
cluded in the calculations of both residence time and dose.
The contribution to mean tumor-absorbed dose from ac-
tivity in the rest of the body within the SPECT FOV ranged
from 14% to 24% for the 6 tumors. The rest-of-the-body
contribution was lowest for the inguinal tumor (Fig. 1C) with
intense focal uptake and was highest for the abdominal
tumor (Fig. 1E), which was in close proximity to normal
organs with significant uptake. This result for patients is
consistent with a previous I-131 phantom study, which
showed that neglecting the photon contribution from the rest
of the body underestimates the tumor dose by 10%–25%.27
Discussion
The rapid regression of some of the tumors in the present
study (up to 49% within a period of 15 days) is consistent
with previous RIT studies showing dramatic shrinkage of
malignant lymphomas within days of the therapeutic ad-
ministration.10,11 In patient 2, significant (up to 23%) re-
gression was measured in post-tracer imaging prior to
therapy administration. In this case, because the tracer ad-
ministration was only 185 MBq, it can be inferred that the
initial tumor shrinkage was in response to the unlabeled
(cold) antibody, which is coadministered with I-131 tositu-
momab and has been shown to have some therapeutic ef-
fect.28 Stunning effects associated with the radioactivity in
the diagnostic dose have been reported in I-131 therapy of
thyroid carcinoma29 but have not been documented in
radioimmunotherapy.
Despite tumor regression, most dosimetry calculations in
radionuclide therapy, patient specific or otherwise, have
been carried out by assuming a constant tumor mass from a
baseline CT (typically obtained a few weeks before start of
treatment). In the present dose calculation, we accounted for
tumor regression by utilizing integrated imaging data from
multiple time points. For comparison, the therapy-delivered
dose, assuming a static CT volume from the initial scan, was
also calculated and was found to underestimate the dose by
up to 47% because of the inverse relationship between dose
and mass at a given uptake. In the present study, reasonable
agreement (within 15%, on average) and correlation
(Pearson’s correlation¼ 0.9) were achieved between the
predicted and delivered doses when the tumor regression
was included in the calculations. A larger study with more
patients is needed to establish the trends observed in the
present study. Agreement between tracer-predicted and
therapy-delivered tumor dose would validate the use of a
tracer study in treatment planning, to predict the radiation
doses that would be received from therapy.
The mean tumor-absorbed doses reported in this article
(ranging from 146 to 334 cGy) are within the range reported
in previous studies on dose response in I-131 tositumomab
therapy of NHL patients.6,7 Estimation of the error in patient
dosimetry results is difficult. However, patient-specific
Monte Carlo–based methods, such as those used in this
study, are known to provide the most accurate dose calcu-
lation, being limited only by the accuracy of their inputs,
which in the present case, were the coregistered quantitative
SPECT image, CT image, and CT-defined tumor outlines.
SPECT-activity quantification of I-131 is particularly chal-
lenging because of spatial-resolution and septal-penetration
Table 2. Summary of Tumor Shrinkage and Mean Tumor-Absorbed Dose from Tracer and Therapy Imaging









Initial tumor volume 313 mL 39 mL 234 mL 140 mL 400 mL 408 mL
Shrinkage
(during tracer imaging)
1% 10% 23% 18% 4% 2%
Shrinkage
(during therapy imaging)
26% 31% 17% 31% 3% 17%
Total shrinkage 31% 27% 45% 49% 5% 15%
Residence time
(using tracer imaging)
2.70 hours 0.41 hours 0.71 hours 0.44 hours 1.11 hours 1.89 hours
Residence time
(using therapy imaging)
2.16 hours 0.25 hours 0.59 hours 0.37 hours 0.85 hours 1.55 hours
Predicted dose
(using tracer imaging)
359 cGy 360 cGy 192 cGy 181 cGy 183 cGy 281 cGy
Delivered dose
(using therapy imaging)
















aDifference between tracer-predicted and therapy-delivered doses.
bDifference between therapy dose estimated by assuming a static tumor volume from the initial computed tomography scan and the result
in the row above, where the tumor regression measured over multiple scans was included in the calculation.
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FIG. 2. Comparison of the computed tomography scans from the first post-tracer (left) and last post-therapy (right) imaging
time points that demonstrate the regression in (A) the pelvic tumors of patient 1 (shrinkage 31% and 21% for the 2 tumors),
(B) the iliac tumor of patient 2 (shrinkage 45%), and (C) the inguinal tumor of patient 2 (shrinkage 49%).
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effects. Using 3D OSEM reconstruction methods, such as
those used in the present work, in previous phantom studies,
we have demonstrated quantitative accuracy better than 10%
for ‘‘tumor’’ volumes down to 16 mL without partial volume
correction.30 In patient studies, SPECT-CT misregistration is
another source of error but is minimized with integrated
imaging systems. We have carried out simulation studies to
investigate the sensitivity of SPECT=CT-imaging-based do-
simetry to misregistration.26 These studies showed that good
accuracy (<3% error for relatively large tumors, such as
those of the present study) can be achieved when concurrent
offsets in three dimensions are <2 mm, which is feasible with
an integrated system. Even with integrated imaging, breath-
ing introduces misregistration, but is less significant when
imaging the pelvis and abdomen region, as in the present
study. In the present study, much emphasis was placed on
careful definition of the tumor at each time point. For 4 of
the 6 tumors, the boundaries were clearly visible on CT
(Fig. 4), but for the other 2, where the tumor was encasing
FIG. 3. Whole-body (within field of view) time–activity
data for patient 1 with a monoexponential fit.
FIG. 4. Tumor time-activity data with biexponential fitting. (A) Patient 1: Large pelvic tumor. (B) Patient 2: Inguinal tumor.
(C) Patient 3: Pelvic tumor. (D) Patient 4: Abdominal tumor.
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and compressing normal anatomic structure or was a con-
glomeration of multiple enlarged nodes, accurate definition
on the low-dose CT acquired without contrast was chal-
lenging. In such cases, the uncertainty in tumor definition
may be a main source of error in the dosimetry calculation.
In the present study, because of the small sample size, no
statistical analysis was carried out to determine the correla-
tion between the absorbed dose to the tumor and response.
This pilot study was the basis for initiating a larger, ongoing
study for evaluating dose response from 50 NHL patients to
be imaged on the integrated system. Apart from the calcu-
lations of mean tumor dose presented in this article, we are
also investigating 3D, time-dependent dosimetry in de-
forming tumor volumes to compute quantities such as ef-
fective uniform dose,15 which may correlate better with
response than mean dose.
Conclusions
This work demonstrates the utility of integrated SPECT=
CT imaging in carrying out highly patient-specific tumor
dosimetry following radioimmunotherapy. Integrated im-
aging and advanced SPECT reconstruction methods were
used to determine the pharmacokinetics and the dosimetry,
incorporating changes in tumor volume in the calculation. In
4 of the 6 tumors analyzed, highly significant regression was
measured within days of the treatment; hence, the compar-
ison calculation assuming a static tumor volume significantly
underestimated the dose. There was reasonable agreement
and correlation between tracer-predicted and therapy-
delivered tumor doses when regression was included in the
calculations, but a larger patient study is needed to establish
these trends.
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